Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/98524
標題: 評估高劑量buprenorphine作為犬隻術後止痛與鎮靜效果
Sedative effects of high dose buprenorphine as a post-operative analgesic in dogs
作者: 許哲榮
Che-Jung Hsu
關鍵字: Buprenorphine

鎮靜效果
視覺類比量表
Buprenorphine
Dogs
Sedative effects
VAS
引用: Abbo LA, Ko DJC, Maxwell LK et al. (2008) Pharmacokinetics of buprenorphine following intravenous and oral transmucosal administration in dogs. Vet Ther 9, 83-93. Adler M, Geller E, Rosow C et al. (1988) The opioid system and temperature regulation. Annu Rev Pharmacol Toxicol 28, 429-449. Allweiler S, Brodbelt DC, Borer K et al. (2007) The isoflurane-sparing and clinical effects of a constant rate infusion of remifentanil in dogs. Vet Anaesth Analg 34, 388-393. Andaluz A, Moll X, Abellán R et al. (2009) Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs. Vet J 181, 299-304. Angst MS, Koppert W, Pahl I et al. (2003) Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 106, 49-57. Aun C, Lam Y, Collett B (1986) Evaluation of the use of visual analogue scale in Chinese patients. Pain 25, 215-221. Böger RH (2006) Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med 20, 17-23. Barbarossa A, Rambaldi J, Giunti M et al. (2017) Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. Vet Anaesth Analg 44, 435-443. Beaton DE, Bombardier C, Guillemin F et al. (2000) Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 25, 3186-3191. Belcheva MM, Barg J, McHALE RJ et al. (1993) Differential down-and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine. Mol Pharmacol 44, 173-179. Benyamin R, Adlaka R, Sehgal N et al. (2008) Opioid complications and side effects. Pain Physician 11, S105-S120. Bernd V, Azriel P, Ulrich J (2002) Clinical review: complications and risk factors of peripheral arterial catheters used for haemodynamic monitoring in anaesthesia and intensive care medicine. Crit Care 6, 198-204. Boas R, Villiger J (1985) Clinical actions of fentanyl and buprenorphine: the significance of receptor binding. Br J Anaesth 57, 192-196. Bodey A, Michell A, Bovee K et al. (1996) Comparison of direct and indirect (oscillometric) measurements of arterial blood pressure in conscious dogs. Res Vet Sci 61, 17-21. Bowdle TA, Ward RJ (1989) Induction of anesthesia with small doses of sufentanil or fentanyl: dose versus EEG response, speed of onset, and thiopental requirement. Anesthesiology 70, 26-30. Breivik H, Collett B, Ventafridda V et al. (2006) Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 10, 287-333. Brodbelt DC, Taylor PM, Stanway GW (1997) A comparison of preoperative morphine and buprenorphine for postoperative analgesia for arthrotomy in dogs. J Vet Pharmacol Ther 20, 284-289. Brondani JT, Mama KR, Luna SP et al. (2013) Validation of the English version of the UNESP-Botucatu multidimensional composite pain scale for assessing postoperative pain in cats. BMC Vet Res 9, 143. Brown SM, Holtzman M, Kim T et al. (2011) Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 115, 1251-1260. Bruera E, Macmillan K, Hanson J et al. (1989) The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 39, 13-16. Budd K (1981) High dose buprenorphine for postoperative analgesia. Anaesthesia 36, 900-903. Célèrier E, Rivat C, Jun Y et al. (2000) Long-lasting hyperalgesia induced by fentanyl in rats preventive effect of ketamine. Anesthesiology 92, 465-472. Chauvin M, Sandouk P, Scherrmann J et al. (1987) Morphine pharmacokinetics in renal failure. Anesthesiology 66, 327-331. Cherny N, Portenoy R (1999) Practical issues in the management of cancer pain. In: Textbook of Pain (4th edn). Wall PD, Melzack R (eds). Churchill Livingstone, Edinburgh. pp. 241. Chevillard L, Mégarbane B, Risède P et al. (2009) Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats. Toxicol Lett 191, 327-340. Christoph T, Kögel B, Schiene K et al. (2005) Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 507, 87-98. Coderre TJ, Katz J, Vaccarino AL et al. (1993) Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 52, 259-285. Congdon JM (2014) Cardiovascular Disease. In: Canine and Feline Anesthesia and Co-existing Disease (1st edn). Snyder LB, Johnson RA (eds). John Wiley and Sons, USA. pp. 1-54. Cowan A, Lewis J, Macfarlane I (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60, 537-545. Cowan A, Lewis JW (1995) Buprenorphine: combatting drug abuse with a unique opioid. Wiley-Liss, Inc., New York. Dahan A (2006) Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med 20, 3-8. Dahan A, Yassen A, Bijl H et al. (2005) Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94, 825-834. Dahan A, Yassen A, Romberg R et al. (2006) Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 96, 627-632. Dobromylskyj P, Flecknell P, Lascelles B et al. (2000) Management of postoperative and other acute pain. In: Pain management in animals (1st edn). Flecknell P, Waterman-Pearson A (eds). Elsevier, USA. pp. 81-145. Downie W, Leatham P, Rhind V et al. (1978) Studies with pain rating scales. Ann Rheum Dis 37, 378-381. Dum JE, Herz A (1981) In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 74, 627-633. England G, Flack T, Hollingworth E et al. (1996) Sedative effects of romifidine in the dog. J Small Anim Pract 37, 19-25. Firth AM, Haldane SL (1999) Development of a scale to evaluate postoperative pain in dogs. J Am Vet Med Assoc 214, 651-659. Gal TJ (1989) Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther 45, 66-71. Greenwald MK, Johanson C-E, Moody DE et al. (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28, 2000-2009. Grimm KA, Tranquilli WJ, Gross DR et al. (2005) Cardiopulmonary effects of fentanyl in conscious dogs and dogs sedated with a continuous rate infusion of medetomidine. Am J Vet Res 66, 1222-1226. Grint N, Burford J, Dugdale A (2009) Does pethidine affect the cardiovascular and sedative effects of dexmedetomidine in dogs? J Small Anim Pract 50, 62-66. Grint NJ, Alderson B, Dugdale AH (2010) A comparison of acepromazine-buprenorphine and medetomidine-buprenorphine for preanesthetic medication of dogs. J Am Vet Med Assoc 237, 1431-1437. Guedes A, Papich M, Rude E et al. (2007) Comparison of plasma histamine levels after intravenous administration of hydromorphone and morphine in dogs. J Vet Pharmacol Ther 30, 516-522. Guedes A, Papich M, Rude E et al. (2008) Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. J Vet Pharmacol Ther 31, 334-343. Guignard B, Bossard AE, Coste C et al. (2000) Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 93, 409-417. Guillemin F, Bombardier C, Beaton D (1993) Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 46, 1417-1432. Guyatt GH, Townsend M, Berman LB et al. (1987) A comparison of Likert and visual analogue scales for measuring change in function. J Chronic Dis 40, 1129-1133. Hand C, Sear J, Uppington J et al. (1990) Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 64, 276-282. Hansen BD (2003) Assessment of pain in dogs: veterinary clinical studies. ILAR J 44, 197-205. Hardy JD, Wolff HG, Goodell H (1950) Experimental evidence on the nature of cutaneous hyperalgesia. J Clin Invest 29, 115-140. Hayes A, Tyers M (1983) Determination of receptors that mediate opiate side effects in the mouse. Br J Pharmacol 79, 731-736. Hendler N, Cimini C, Ma T et al. (1980) A comparison of cognitive impairment due to benzodiazepines and to narcotics. Am J psychiatry 137, 828-830. Holton LL, Scott E, Nolan AM et al. (1998) Comparison of three methods used for assessment of pain in dogs. J Am Vet Med Assoc 212, 61-66. Hood DD, Curry R, Eisenach JC (2003) Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia. Anesth Analg 97, 810-815. Hoskin P, Hanks G (1991) Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 41, 326-344. Hunt JR, Grint NJ, Taylor PM et al. (2013) Sedative and analgesic effects of buprenorphine, combined with either acepromazine or dexmedetomidine, for premedication prior to elective surgery in cats and dogs. Vet Anaesth Analg 40, 297-307. Huskisson E (1974) Measurement of pain. Lancet 304, 1127-1131. Inturrisi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18, S3-S13. Jarzyna D, Jungquist CR, Pasero C et al. (2011) American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. Pain Manag Nurs 12, 118-145. Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 35, 501-516. Jensen MP, Karoly P, Braver S (1986) The measurement of clinical pain intensity: a comparison of six methods. Pain 27, 117-126. Jordan C (1982) Assessment of the effects of drugs on respiration. Br J Anaesth 54, 763-782. Kögel B, Christoph T, Strassburger W et al. (2005) Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain 9, 599-611. Kästner S (2007) Intravenous anaesthetics. In: Manual of Canine and Feline Anaesthesia and Analgesia (2nd edn). Seymour C, Duke-Novakovski T (eds). BSAVA, UK. pp. 133-149. Kawamoto H, Ozaki S, Itoh Y et al. (1999) Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3 R, 4 R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2 H-benzimidazol-2-one (J-113397). J Med Chem 42, 5061-5063. Kerr C (2007) Pain management I: systemic analgesics. In: Manual of Canine and Feline Anaesthesia and Analgesia (2nd edn). Seymour C, Duke-Novakovski T (eds). BSAVA, UK. pp. 89-104. Kitchell R (1987) Problems in defining pain and peripheral mechanisms of pain. J Am Vet Med Assoc 191, 1195-1199. Ko JC, Freeman LJ, Barletta M et al. (2011) Efficacy of oral transmucosal and intravenous administration of buprenorphine before surgery for postoperative analgesia in dogs undergoing ovariohysterectomy. J Am Vet Med Assoc 238, 318-328. Koppert W, Dern SK, Sittl R et al. (2001) A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S (+)-ketamine, and lidocaine. Anesthesiology 95, 395-402. Koppert W, Ihmsen H, Körber N et al. (2005) Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 118, 15-22. Kremer E, Atkinson JH, Ignelzi R (1981) Measurement of pain: patient preference does not confound pain measurement. Pain 10, 241-248. Kress HG (2009) Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 13, 219-230. KuKanich B, Wiese AJ (2015) Opioids. In: Lumb and Jones' Veterinary Anesthesia and Analgesia (5th edn). Grimm KA, Lamont LA, Tranquilli WJ, Greene SA, Robertson SA (eds). Wiley-Blackwell, USA. pp. 207-226. Kurella M, Bennett WM, Chertow GM (2003) Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis 42, 217-228. Kuusela E, Raekallio M, Väisänen M et al. (2001a) Comparison of medetomidine and dexmedetomidine as premedicants in dogs undergoing propofol-isoflurane anesthesia. Am J Vet Res 62, 1073-1080. Kuusela E, Vainio O, Kaistinen A et al. (2001b) Sedative, analgesic, and cardiovascular effects of levomedetomidine alone and in combination with dexmedetomidine in dogs. Am J Vet Res 62, 616-621. Lamont L, Mathews K (2007) Opioids, nonsteroidal anti-inflammatories, and analgesic adjuvants. In: Lumb and Jones' Veterinary Anesthesia and Analgesia (4th edn). Tranquilli WJ, Thurmon JC, Grimm KA (eds). Wiley-Blackwell, USA. pp. 241-271. Lee KO, Akil H, Woods JH et al. (1999) Differential binding properties of oripavines at cloned mu-and delta-opioid receptors. Eur J Pharmacol 378, 323-330. Lewis KA, Bednarski RM, Aarnes TK et al. (2014) Postoperative comparison of four perioperative analgesia protocols in dogs undergoing stifle joint surgery. J Am Vet Med Assoc 244, 1041-1046. Linton D, Wilson M, Newbound G et al. (2012) The effectiveness of a long-acting transdermal fentanyl solution compared to buprenorphine for the control of postoperative pain in dogs in a randomized, multicentered clinical study. J Vet Pharmacol Ther 35, 53-64. Lizasoain I, Leza JC, Lorenzo P (1991) Buprenorphine: Bell-shaped dose-response curve for its antagonist effects. Gen Pharmacol 22, 297-300. Lorena SE, Luna SP, Lascelles BDX et al. (2014) Current attitudes regarding the use of perioperative analgesics in dogs and cats by Brazilian veterinarians. Vet Anaesth Analg 41, 82-89. Lukasik V (1999) Premedication and sedation. In: Manual of Canine and Feline Anaesthesia and Analgesia (1st edn). Seymour C, Gleed R (eds). BSAVA, UK. pp. 71-86. Lutfy K, Eitan S, Bryant CD et al. (2003) Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23, 10331-10337. Lutfy K, Maidment NT (2000) Blockade of mu‐opioid receptors reveals the hyperalgesic effect of orphanin FQ/nociceptin in the rat hot plate test. Br J Pharmacol 131, 1684-1688. Möhler H, Richards J (1988) The benzodiazepine receptor: a pharmacological control element of brain function. Eur J Anaesthesiol Suppl 2, 15-24. Martin WR (1983) Pharmacology of opioids. Pharmacol Rev 35, 283-323. Martin WR, Eades CG, Thompson JA et al. (1976) The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197, 517-532. Mathews KA (2000) Pain assessment and general approach to management. Vet Clin North Am Small Anim Pract 30, 729-755. Mercadante S, Villari P, Ferrera P et al. (2006) Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage 32, 175-179. Mishina M, Watanabe T, Fujii K et al. (1997) A clinical evaluation of blood pressure through non-invasive measurement using the oscillometric procedure in conscious dogs. J Vet Med Sci 59, 989-993. Mogil JS, Pasternak GW (2001) The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 53, 381-415. Monteiro ER, Junior AR, Assis HMQ et al. (2009) Comparative study on the sedative effects of morphine, methadone, butorphanol or tramadol, in combination with acepromazine, in dogs. Vet Anaesth Anal 36, 25-33. Morgan D, Cook CD, Smith MA et al. (1999) An examination of the interactions between the antinociceptive effects of morphine and various mu-opioids: the role of intrinsic efficacy and stimulus intensity. Anesth Analg 88, 407-413. Murphy MR, Olson WA, Hug JC (1979) Pharmacokinetics of 3H-fentanyl in the dog anesthetized with enflurane. Anesthesiology 50, 13-19. Nemirovsky A, Chen L, Zelman V et al. (2001) The antinociceptive effect of the combination of spinal morphine with systemic morphine or buprenorphine. Anesth Analg 93, 197-203. Nisbet AT, Mooney-Cotter F (2009) Comparison of selected sedation scales for reporting opioid-induced sedation assessment. Pain Manag Nurs 10, 154-164. Ocaña M, Pozo E, Barrios M et al. (1995) Subgroups among mu-opioid receptor agonists distinguished by ATP-sensitive K+ channel-acting drugs. Br J Pharmacol 114, 1296-1302. Ogon M, Krismer M, Söllner W et al. (1996) Chronic low back pain measurement with visual analogue scales in different settings. Pain 64, 425-428. Ohnhaus EE, Adler R (1975) Methodological problems in the measurement of pain: a comparison between the verbal rating scale and the visual analogue scale. Pain 1, 379-384. Ohtani M, Kotaki H, Nishitateno K et al. (1997) Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 281, 428-433. Oifa S, Sydoruk T, White I et al. (2009) Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery. Clin Ther 31, 527-541. Osborne R, Joel S, Grebenik K et al. (1993) The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 54, 158-167. Pace NL, Parrish RG, Lieberman MM et al. (1979) Pharmacokinetics of naloxone and naltrexone in the dog. J Pharmacol Exp Ther 208, 254-256. Park I, Kim D, Song J et al. (2008) Buprederm, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies. Pharm Res 25, 1052-1062. Pascoe PJ (2000) Perioperative pain management. Vet Clin North Am Sm Anim Pract 30, 917-932. Pasero C (2009) Assessment of sedation during opioid administration for pain management. J Perianesth Nurs 24, 186-190. Pasternak GW, Pan YX (2013) Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 65, 1257-1317. Pergolizzi J, Aloisi AM, Dahan A et al. (2010) Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 10, 428-450. Raekallio M, Heinonen KM, Kuussaari J et al. (2003) Pain alleviation in animals: attitudes and practices of Finnish veterinarians. Vet J 165, 131-135. Raffa RB, Ding Z (2007) Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist. Acute Pain 9, 145-152. Reisine T, Pasternak G (1996) Opioid analgesics and antagonists. In: The Pharmacological Basis of Therapeutics (9th edn). Hradman J, Limbird L (eds). McGraw-Hill, USA. pp. 521-555. Robertson S, Lascelles B, Taylor P et al. (2005) PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration. J Vet Pharmacol Ther 28, 453-460. Sawyer D, Brown M, Striler E et al. (1991) Comparison of direct and indirect blood pressure measurement in anesthetized dogs. Lab Anim Sci 41, 134-138. Scott J, Huskisson E (1979) Vertical or horizontal visual analogue scales. Ann Rheum Dis 38, 560. Selley DE, Liu Q, Childers SR (1998) Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S] GTP gamma S binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther 285, 496-505. Simon N, Urien S, Riou B et al. (2009) Intravenous morphine titration in immediate postoperative pain management: population kinetic-pharmacodynamic and logistic regression analysis. Pain 144, 139-146. Slingsby L, Taylor P, Waterman-Pearson A (2006) Effects of two doses of buprenorphine four or six hours apart on nociceptive thresholds, pain and sedation in dogs after castration. Vet Rec 159, 705-711. Slingsby LS, Taylor PM, Murrell JC (2011) A study to evaluate buprenorphine at 40 μg kg-1 compared to 20 μg kg-1 as a post-operative analgesic in the dog. Vet Anaesth Analg 38, 584-593. Smith LJ, Yu JK, Bjorling DE et al. (2001) Effects of hydromorphone or oxymorphone, with or without acepromazine, on preanesthetic sedation, physiologic values, and histamine release in dogs. J Am Vet Med Assoc 218, 1101-1105. Snow S, Kirwan J (1988) Visual analogue scales: a source of error. Ann Rheum Dis 47, 526. Snyder SH, Pasternak GW (2003) Historical review: opioid receptors. Trends Pharmacol Sci 24, 198-205. Sousa VD, Rojjanasrirat W (2011) Translation, adaptation and validation of instruments or scales for use in cross-cultural health care research: a clear and user-friendly guideline. J Eval Clin Pract 17, 268-274. Steffey EP, Mama KR, Brosnan RJ (2015) Inhalation anesthetics. In: Lumb and Jones' Veterinary Anesthesia and Analgesia (5th edn). Grimm KA, Lamont LA, Tranquilli WJ, Greene SA, Robertson SA (eds). Wiley-Blackwell, USA. pp. 297-323. Taylor P (1985) Analgesia in the dog and cat. In pract 17, 5-13. Taylor PM, Houlton JEF (1984) Post-operative analgesia in the dog: a comparison of morphine, buprenorphine and pentazocine. J Small Anim Pract 25, 437-451. Taylor S, Voytovich AE, Kozol RA (2003) Has the pendulum swung too far in postoperative pain control? Am J Surg 186, 472-475. Tian JH, Xu W, Fang Y et al. (1997) Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br J Pharmacol 120, 676-680. Tröster A (2004) Quantifizierung analgetischer und antihyperalgetischer Effekte von Buprenorphin und Fentanyl am Menschen. Schmerz 18, 72. Vachon C, Belanger MC, Burns PM (2014) Evaluation of oscillometric and Doppler ultrasonic devices for blood pressure measurements in anesthetized and conscious dogs. Res Vet Sci 97, 111-117. Valverde A, Cantwell S, Hernández J et al. (2004) Effects of acepromazine on the incidence of vomiting associated with opioid administration in dogs. Vet Anaesth Analg 31, 40-45. Van Dorp E, Yassen A, Sarton E et al. (2006) Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology 105, 51-57. Vanderah TW, Gardell LR, Burgess SE et al. (2000) Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 20, 7074-7079. Wagner MC, Hecker KG, Pang DS (2017) Sedation levels in dogs: a validation study. BMC Vet Res 13, 110. Wilson DV (1992) Advantages and guidelines for using opioid agonists for induction of anesthesia. Vet Clin North Am Small Anim Pract 22, 269-272. Yassen A, Olofsen E, Kan J et al. (2008) Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res 25, 183-193. Yassen A, Olofsen E, van Dorp E et al. (2007) Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone: a study in healthy volunteers. Clin Pharmacokinet 46, 965-980. Yassen A, Olofsen E, Romberg R et al. (2006) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 104, 1232-1242. Young-McCaughan S, Miaskowski C (2001) Definition of and mechanism for opioid-induced sedation. Pain Manag Nurs 2, 84-97. Zaki PA, Keith DE, Brine GA et al. (2000) Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther 292, 1127-1134.
摘要: Buprenorphine為廣泛應用於獸醫止痛的半合成蒂巴因衍生物,其被歸類為部分致效劑,基於對μ鴉片類受體的高親和力和低內在活性。近年來的研究顯示buprenorphine對於止痛可作為一種完全致效劑且無頂峰效應。然而給予高於臨床建議劑量的buprenorphine可能導致較大的副作用,因此本實驗的目的便是評估高劑量buprenorphine於犬隻的術後鎮靜效果。十五隻自國立中興大學獸醫教學醫院進行去勢的雄性狗被隨機分為buprenorphine 40 (B40組,n=7)或60 μg/kg (B60組,n=8),結束麻醉並降體溫回復至大於37.8 ℃後,給予靜脈注射分組劑量的buprenorphine作為術後止痛。使用視覺類比量表(VAS)和複合型鎮靜評分系統評估鎮靜分數,於基準值(給藥前)至給藥後12小時記錄測量值、生理參數和疼痛分數。鎮靜效果在給藥後1小時內迅速上升至最大值,其後隨著時間推移而下降,兩組於給藥後4至6小時顯著增加鎮靜程度。B60組相較於B40組呈現較高的鎮靜程度且較長的作用時間,然而兩組之間的差異並不顯著。在整個實驗期間並沒有觀察到對心血管和呼吸系統等有害副作用,也無任何狗需給予救援止痛。根據實驗結果,在給予buprenorphine 40和60 μg/kg後會顯著誘發鎮靜效果,任一劑量的buprenorphine皆足夠提供去勢後長達12小時的止痛。
Buprenorphine is a semi-synthetic thebaine derivative that broadly employed for analgesia in veterinary medicine. It is classified as partial μ-opioid agonist based on high affinity and low intrinsic activity to the receptor. Recent studies have demonstrated that buprenorphine acts as a full agonist with no ceiling effect on analgesia. However, administration of buprenorphine above the recommended dosage may induce greater adverse reactions. Therefore, the aim of this study is to evaluate the post-operative sedative effects of high dose buprenorphine in dogs. Fifteen male dogs from the NCHU-VMTH for castration were enrolled and randomized to either buprenorphine 40 (B40 group, n = 7) or 60 μg/kg (B60 group, n = 8). After anesthesia and rewarmed body temperature to over 37.8℃, relevant doses of buprenorphine for each group were intravenously administered for post-operative analgesia. Sedation was evaluated using VAS and a multi-dimensional sedation scoring system. Measurements along with vital parameters and pain scores were recorded at baseline (prior to treatment) and up to 12 hours after administration. Sedative effects rapidly elevated to maximum at 1 hour and then fell over time, significant increase in levels of sedation reached 4 to 6 hours after administration of both treatments. B60 group showed promotion of sedative effects and also prolonged the duration of action compared to B40 group; however, the enhancements were not significant among two treatments. No detrimental effects on cardiovascular and respiratory system were observed and none of the dog required rescue analgesia throughout the study. In conclusion, administration of buprenorphine at 40 and 60 μg/kg can significantly induced sedation. Either dose of buprenorphine provides sufficient analgesia for up to 12 hours after castration.
URI: http://hdl.handle.net/11455/98524
文章公開時間: 2018-08-07
Appears in Collections:獸醫學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.